These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

704 related articles for article (PubMed ID: 34233096)

  • 21. The long road.
    Cohen J
    Science; 2021 Feb; 371(6531):768-772. PubMed ID: 33602838
    [No Abstract]   [Full Text] [Related]  

  • 22. Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2.
    Lustig Y; Nemet I; Kliker L; Zuckerman N; Yishai R; Alroy-Preis S; Mendelson E; Mandelboim M
    N Engl J Med; 2021 Jun; 384(25):2453-2454. PubMed ID: 33826815
    [No Abstract]   [Full Text] [Related]  

  • 23. Audio Interview: New Evidence on SARS-CoV-2 Vaccine Boosters.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2021 Sep; 385(12):e48. PubMed ID: 34525292
    [No Abstract]   [Full Text] [Related]  

  • 24. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine.
    Krammer F; Srivastava K; Alshammary H; Amoako AA; Awawda MH; Beach KF; Bermúdez-González MC; Bielak DA; Carreño JM; Chernet RL; Eaker LQ; Ferreri ED; Floda DL; Gleason CR; Hamburger JZ; Jiang K; Kleiner G; Jurczyszak D; Matthews JC; Mendez WA; Nabeel I; Mulder LCF; Raskin AJ; Russo KT; Salimbangon AT; Saksena M; Shin AS; Singh G; Sominsky LA; Stadlbauer D; Wajnberg A; Simon V
    N Engl J Med; 2021 Apr; 384(14):1372-1374. PubMed ID: 33691060
    [No Abstract]   [Full Text] [Related]  

  • 25. Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine.
    Bradley T; Grundberg E; Selvarangan R; LeMaster C; Fraley E; Banerjee D; Belden B; Louiselle D; Nolte N; Biswell R; Pastinen T; Myers A; Schuster J
    N Engl J Med; 2021 May; 384(20):1959-1961. PubMed ID: 33755375
    [No Abstract]   [Full Text] [Related]  

  • 26. Comparing Immune Responses to Inactivated Vaccines against SARS-CoV-2 between People Living with HIV and HIV-Negative Individuals: A Cross-Sectional Study in China.
    Huang X; Yan Y; Su B; Xiao D; Yu M; Jin X; Duan J; Zhang X; Zheng S; Fang Y; Zhang T; Tang W; Wang L; Wang Z; Xu J
    Viruses; 2022 Jan; 14(2):. PubMed ID: 35215870
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons.
    Rössler A; Riepler L; Bante D; von Laer D; Kimpel J
    N Engl J Med; 2022 Feb; 386(7):698-700. PubMed ID: 35021005
    [No Abstract]   [Full Text] [Related]  

  • 28. Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.
    Widge AT; Rouphael NG; Jackson LA; Anderson EJ; Roberts PC; Makhene M; Chappell JD; Denison MR; Stevens LJ; Pruijssers AJ; McDermott AB; Flach B; Lin BC; Doria-Rose NA; O'Dell S; Schmidt SD; Neuzil KM; Bennett H; Leav B; Makowski M; Albert J; Cross K; Edara VV; Floyd K; Suthar MS; Buchanan W; Luke CJ; Ledgerwood JE; Mascola JR; Graham BS; Beigel JH;
    N Engl J Med; 2021 Jan; 384(1):80-82. PubMed ID: 33270381
    [No Abstract]   [Full Text] [Related]  

  • 29. The Flawed Science of Antibody Testing for SARS-CoV-2 Immunity.
    Abbasi J
    JAMA; 2021 Nov; 326(18):1781-1782. PubMed ID: 34673883
    [No Abstract]   [Full Text] [Related]  

  • 30. Developing Immunity Testing for SARS-CoV-2 and Other Novel Vaccines-Correlates of Immunogenicity Parameters with Protection.
    Vajo Z
    Viruses; 2022 Jan; 14(2):. PubMed ID: 35215791
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients.
    Hall VG; Ferreira VH; Ku T; Ierullo M; Majchrzak-Kita B; Chaparro C; Selzner N; Schiff J; McDonald M; Tomlinson G; Kulasingam V; Kumar D; Humar A
    N Engl J Med; 2021 Sep; 385(13):1244-1246. PubMed ID: 34379917
    [No Abstract]   [Full Text] [Related]  

  • 32. Durability of XBB.1.5 Vaccines against Omicron Subvariants.
    Lin DY; Du Y; Xu Y; Paritala S; Donahue M; Maloney P
    N Engl J Med; 2024 Jun; 390(22):2124-2127. PubMed ID: 38810167
    [No Abstract]   [Full Text] [Related]  

  • 33. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
    Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
    Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Audio Interview: Antibody Responses to Natural Infection and Vaccination.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2021 Apr; 384(14):e65. PubMed ID: 33826826
    [No Abstract]   [Full Text] [Related]  

  • 35. A third booster dose may be necessary to mitigate neutralizing antibody fading after inoculation with two doses of an inactivated SARS-CoV-2 vaccine.
    Yue L; Xie T; Yang T; Zhou J; Chen H; Zhu H; Li H; Xiang H; Wang J; Yang H; Zhao H; Wei X; Zhang Y; Xie Z
    J Med Virol; 2022 Jan; 94(1):35-38. PubMed ID: 34516026
    [No Abstract]   [Full Text] [Related]  

  • 36. Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351.
    Shen X; Tang H; Pajon R; Smith G; Glenn GM; Shi W; Korber B; Montefiori DC
    N Engl J Med; 2021 Jun; 384(24):2352-2354. PubMed ID: 33826819
    [No Abstract]   [Full Text] [Related]  

  • 37. Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine.
    Wu K; Werner AP; Koch M; Choi A; Narayanan E; Stewart-Jones GBE; Colpitts T; Bennett H; Boyoglu-Barnum S; Shi W; Moliva JI; Sullivan NJ; Graham BS; Carfi A; Corbett KS; Seder RA; Edwards DK
    N Engl J Med; 2021 Apr; 384(15):1468-1470. PubMed ID: 33730471
    [No Abstract]   [Full Text] [Related]  

  • 38. Neutralizing Activity of BNT162b2-Elicited Serum.
    Liu Y; Liu J; Xia H; Zhang X; Fontes-Garfias CR; Swanson KA; Cai H; Sarkar R; Chen W; Cutler M; Cooper D; Weaver SC; Muik A; Sahin U; Jansen KU; Xie X; Dormitzer PR; Shi PY
    N Engl J Med; 2021 Apr; 384(15):1466-1468. PubMed ID: 33684280
    [No Abstract]   [Full Text] [Related]  

  • 39. Letter to the Editor Regarding "Comparative Immunogenicity and Neutralization Potency of Four Approved COVID-19 Vaccines in BALB/c Mice".
    Daungsupawong H; Wiwanitkit V
    Iran J Immunol; 2024 Jun; 21(2):184-185. PubMed ID: 38803238
    [No Abstract]   [Full Text] [Related]  

  • 40. Inactivated SARS-CoV-2 vaccines elicit immunogenicity and T-cell responses in people living with HIV.
    Lv Z; Li Q; Feng Z; Zheng X; NaYin ; Yang H; Gu Q; Ying S; Qi Y; Li X; Wu R; Wu Z; Yu X; Zou N; Qin D; Wan C
    Int Immunopharmacol; 2022 Jan; 102():108383. PubMed ID: 34824035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.